Topcon Medical Systems, Inc
Oakland, New Jersey – October 12, 2010 –
Topcon announced today that it recently signed an exclusive
distribution agreement with Optical Imaging Ltd. (Rehovot Israel, Israel) for its Retinal Function Imager (RFI)
system. The agreement enables Topcon to market and sell the RFI system in the United States.
The RFI is a non‐invasive, ophthalmic functional imaging system with unique capabilities that enable the
clinician or researcher to map the retina to the resolution of red blood cells moving through capillaries. This
enables a clear insight into the pathogenesis of retinal diseases to allow for better patient care. The system
also features software modules that can capture, analyze, store and retrieve patient images and history
information, improving workflow and accessibility. The RFI 3000 model features blood flow velocity and
capillary perfusion maps, while the RFI 3005, currently a research only device features the additional
capabilities of multi‐spectral imaging for retinal oximetry, metabolic functional imaging and patterned
photic stimulation. The first system has been cleared by the FDA for sale in the United States.
Dr. Richard B. Rosen, who chaired a roundtable presenting the latest findings with RFI during the recent
American Society of Retinal Specialists Congress in Vancouver, Canada, is excited about the potential
applications of RFI in patients with retinal disorders. “With the RFI you can measure real velocities of blood
flow in all of the macular vessels with a single multi‐flash sequence of fundus images. It’s possible to view
video loops of red blood cells moving through medium and small size vessels down to the capillary level
and visualize dynamic details of circulatory pathways with greater detail than with fluorescein angiography
(FA) using its unique non‐contrast capillary perfusion maps,” he said. “These studies complement FA,
providing quantitative parameters which can be used to non‐invasively track progression of diabetic and
vascular occlusive disease and measure response to treatment. With Topcon’s support, I am hopeful that
the RFI will be further developed to enhance its user interface and make it more rapidly accessible for
mainstream clinical care.”
Over the coming months, the newly established Functional Imaging Working Group will engage in clinical
research surrounding metabolic function imaging and its implications in the management of various
ophthalmic diseases. “The capabilities presented by the RFI system have the potential to significantly
expand the field of functional imaging of the retina,” said Robert Gibson, Senior Director of Marketing for
Topcon Medical Systems. “The Functional Imaging Working Group was created to give our customers the
necessary information on how best to adopt the RFI system into their clinical practice and to explore new
clinical applications for this exciting new field of retinal imaging.”
For further information please contact:
Linda Dunlea, Media/PR Coordinator, Topcon Medical Systems Inc.: [email protected]
About Topcon Medical Systems, Inc.
Based in Oakland, NJ, Topcon Medical Systems (TMS) is a leader and technical innovator in the field of
ophthalmic instrumentation. For over 39 years, TMS has offered the most complete and technically
advanced line of ophthalmic equipment in the US marketplace. This equipment comprises the largest
selection of precision ophthalmic and optical instruments from one manufacturer, providing a complete
range of products for general and specialized applications. TMS manages ophthalmic dealer sales,
corporate sales, and the Advanced Technology Products Division. TMS is a division of Topcon America
Corporation, a wholly owned subsidiary of Topcon Corporation of Tokyo, Japan.
About Optical Imaging Ltd.
Optical Imaging Ltd. is dedicated to introducing to the medical community novel diagnostic equipment that
provides new early diagnostic capabilities and new insights into ophthalmic diseases, enabling targeted
treatment, clinical follow‐up and enhanced drug development.